Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMAG-423 in Severe Preeclampsia
NCT03008616Phase 3Terminated
- Sponsor
- AMAG Pharmaceuticals, Inc.
- Start
- Apr 2017
- Primary completion
- Aug 2020
- Modality
- Antibody Fragments, Recombinant Proteins and Enzymes
- Countries
- 3
01
Overview
A Phase 3 trial of digoxin immune fab in preeclampsia, sponsored by AMAG Pharmaceuticals, Inc.. Started Apr 2017; status: terminated.
02
Drugs
digoxin immune fab
03
Conditions
preeclampsia
Beyond the preview
Go deeper on NCT03008616.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03008616.